title: Human papillomavirus vaccine: safe, effective, underused.
abstract: Vaccination against human papillomavirus (HPV) is safe and effective. It is recommended for females age 9 to 26 and for males age 11 to 26, yet vaccination rates are low. We review the host immune response, the data behind the recommendations for HPV vaccination, and the challenges of implementing the vaccination program.
authors.affiliation: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. jinx@ccf.org
authors.forename: Xian Wen
authors.initials: XW
authors.lastname: Jin
authors.forename: Laura
authors.initials: L
authors.lastname: Lipold
authors.forename: Andrea
authors.initials: A
authors.lastname: Sikon
authors.forename: Ellen
authors.initials: E
authors.lastname: Rome
mesh_terms: D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control; D014611:Vaccination / Q000706:statistics & numerical data
chemical_list: D053918:Papillomavirus Vaccines